Mone Zaidi

List of Publications by Year
in descending order

278 papers	14,391 citations	19608 61 h-index	26548 107 g-index
337 all docs	337 docs citations	337 times ranked	13579 citing authors

#	Article	IF	Citations
1	Skeletal remodeling in health and disease. Nature Medicine, 2007, 13, 791-801.	15.2	893
2	FSH Directly Regulates Bone Mass. Cell, 2006, 125, 247-260.	13.5	612
3	TSH Is a Negative Regulator of Skeletal Remodeling. Cell, 2003, 115, 151-162.	13.5	585
4	The myokine irisin increases cortical bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12157-12162.	3.3	372
5	Genotypeâ€"phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2611-2616.	3.3	317
6	Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNA in Maternal Plasma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1022-E1030.	1.8	270
7	Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature, 2017, 546, 107-112.	13.7	250
8	Oxytocin is an anabolic bone hormone. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7149-7154.	3.3	223
9	â€˜Calcium-activatedâ€™ intracellular calcium elevation: A novel mechanism of osteoclast regulation. Biochemical and Biophysical Research Communications, 1989, 163, 1461-1465.	1.0	217
10	Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Human Molecular Genetics, 2007, 16, 1113-1123.	1.4	202
11	Molecular regulation of mechanotransduction. Biochemical and Biophysical Research Communications, 2005, 328, 751-755.	1.0	198
12	Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19473-19478.	3.3	198
13	Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. Journal of Clinical Investigation, 2003, 112, 924-934.	3.9	192
14	Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14925-14930.	3.3	191
15	Stimulation of osteoclastic bone resorption by hydrogen peroxide. Biochemical and Biophysical Research Communications, 1992, 183, 1153-1158.	1.0	190
16	Mitochondria to nucleus stress signaling. Journal of Cell Biology, 2003, 161, 507-519.	2.3	169
17	Calcitonin gene-related peptide inhibits osteoclastic bone resorption: A comparative study. Calcified Tissue International, 1987, 40, 149-154.	1.5	162
18	A new function for CD38/ADP-ribosyl cyclase in nuclear Ca2+ homeostasis. Nature Cell Biology, 1999, 1, 409-414.	4.6	159

#	Article	IF	Citations
19	BMP-12 Treatment of Adult Mesenchymal Stem Cells In Vitro Augments Tendon-Like Tissue Formation and Defect Repair In Vivo. PLoS ONE, 2011, 6, e17531.	1.1	154
20	Osteoclastogenesis, Bone Resorption, and Osteoclast-Based Therapeutics. Journal of Bone and Mineral Research, 2003, 18, 599-609.	3.1	151
21	Osteoclast signalling pathways. Biochemical and Biophysical Research Communications, 2005, 328, 728-738.	1.0	145
22	Calcineurin regulates bone formation by the osteoblast. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17130-17135.	3.3	144
23	Mechanisms balancing skeletal matrix synthesis and degradation. Biochemical Journal, 2002, 364, 329-341.	1.7	141
24	ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8782-8787.	3.3	134
25	Forty years of calcitoninâ€"where are we now? A tribute to the work of Iain Macintyre, FRS. Bone, 2002, 30, 655-663.	1.4	132
26	Translational musculoskeletal science: Is sarcopenia the next clinical target after osteoporosis?. Annals of the New York Academy of Sciences, 2011, 1237, 95-105.	1.8	131
27	FSH blockade improves cognition in mice with Alzheimerâ€™s disease. Nature, 2022, 603, 470-476.	13.7	131
28	Blocking antibody to the Î²-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14574-14579.	3.3	129
29	In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochemical and Biophysical Research Communications, 1989, 162, 876-881.	1.0	121
30	Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18644-18649.	3.3	120
31	Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4289-4294.	3.3	118
32	TNFÂ mediates the skeletal effects of thyroid-stimulating hormone. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12849-12854.	3.3	114
33	FSH-receptor isoforms and FSH-dependent gene transcription in human monocytes and osteoclasts. Biochemical and Biophysical Research Communications, 2010, 394, 12-17.	1.0	109
34	Structureâ€"phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2605-2610.	3.3	107
35	Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11Î²-hydroxylase deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1933-E1940.	3.3	106
36	Role of mitochondrial reactive oxygen species in osteoclast differentiation. Annals of the New York Academy of Sciences, 2010, 1192, 245-252.	1.8	101

#	Article	IF	Citations
37	Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11115-11120.	3.3	101
38	Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology, 2008, 35, 488-97.	1.0	99
39	EFFECTS OF PEPTIDES FROM THE CALCITONIN GENES ON BONE AND BONE CELLS. Quarterly Journal of Experimental Physiology (Cambridge, England), 1988, 73, 471-485.	1.0	98
40	Divalent cations mimic the inhibitory effect of extracellular ionised calcium on bone resorption by isolated rat osteoclasts: Further evidence for a ?calcium receptor?. Journal of Cellular Physiology, 1991, 149, 422-427.	2.0	95
41	Disorders Associated With Acute Rapid and Severe Bone Loss. Journal of Bone and Mineral Research, 2003, 18, 2083-2094.	3.1	94
42	Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochemical and Biophysical Research Communications, 2007, 355, 307-311.	1.0	94
43	Inhibition of osteoclastic acid phosphatase abolishes bone resorption. Biochemical and Biophysical Research Communications, 1989, 159, 68-71.	1.0	92
44	Emerging Insights into the Role of Calcium Ions in Osteoclast Regulation. Journal of Bone and Mineral Research, 1999, 14, 669-674.	3.1	92
45	The Calcitonin Gene Peptides: Biology and Clinical Relevance. Critical Reviews in Clinical Laboratory Sciences, 1990, 28, 109-174.	2.7	86
46	Mode of Action of Interleukin-6 on Mature Osteoclasts. Novel Interactions with Extracellular Ca2+ Sensing in the Regulation of Osteoclastic Bone Resorption. Journal of Cell Biology, 1998, 142, 1347-1356.	2.3	85
47	Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4934-4939.	3.3	85
48	Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. Journal of Clinical Investigation, 2012, 122, 3737-3741.	3.9	83
49	The Thyroid-Stimulating Hormone Receptor: Impact of Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Antibodies on Multimerization, Cleavage, and Signaling. Endocrinology and Metabolism Clinics of North America, 2009, 38, 319-341.	1.2	79
50	Adenosine A₁ receptors regulate bone resorption in mice: Adenosine A₁ receptor blockade or deletion increases bone density and prevents ovariectomyâ€induced bone loss in adenosine A₁ receptorâ€“knockout mice. Arthritis and Rheumatism, 2010, 62, 534-541.	6.7	79
51	Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 130-136.	1.4	78
52	The effect of extracellular calcium elevation on morphology and function of isolated rat osteoclasts. Bioscience Reports, 1989, 9, 747-751.	1.1	77
53	Cd38/Adp-Ribosyl Cyclase. Journal of Cell Biology, 1999, 146, 1161-1172.	2.3	76
54	Physiological loading of joints prevents cartilage degradation through CITED2. FASEB Journal, 2011, 25, 182-191.	0.2	74

#	Article	IF	Citations
55	ACTH is a novel regulator of bone mass. Annals of the New York Academy of Sciences, 2010, 1192, 110-116.	1.8	73
56	Disordered osteoclast formation and function in a CD38 (ADPâ€ribosyl cyclase)â€deficient mouse establishes an essential role for CD38 in bone resorption. FASEB Journal, 2003, 17, 369-375.	0.2	72
57	Gaucher disease gene<i>GBA</i>functions in immune regulation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10018-10023.	3.3	70
58	Bone Marrow Oxytocin Mediates the Anabolic Action of Estrogen on the Skeleton. Journal of Biological Chemistry, 2012, 287, 29159-29167.	1.6	66
59	Cathepsin K, Osteoclastic Resorption, and Osteoporosis Therapy. Journal of Bone and Mineral Research, 2001, 16, 1747-1749.	3.1	65
60	A novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca2+signaling via CD38/ADPâ€ribosyl cyclase, a putative intracellular NAD+sensor. FASEB Journal, 2002, 16, 302-314.	0.2	65
61	Epitope-specific monoclonal antibodies to FSHÎ² increase bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2192-2197.	3.3	65
62	Calcitonin and bone formation: a knockout full of surprises. Journal of Clinical Investigation, 2002, 110, 1769-1771.	3.9	64
63	Osteoblast regulation via ligand-activated nuclear trafficking of the oxytocin receptor. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16502-16507.	3.3	63
64	The Influence of Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor Antibodies on Osteoclastogenesis. Thyroid, 2011, 21, 897-906.	2.4	62
65	Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16277-16282.	3.3	60
66	Osteoclastic differentiation and function regulated by old and new pathways. Reviews in Endocrine and Metabolic Disorders, 2007, 7, 23-32.	2.6	59
67	Regulation of Skeletal Homeostasis. Endocrine Reviews, 2018, 39, 701-718.	8.9	59
68	TNF regulates cellular NAD+ metabolism in primary macrophages. Biochemical and Biophysical Research Communications, 2006, 342, 1312-1318.	1.0	58
69	Calcium and bone disease. BioFactors, 2011, 37, 159-167.	2.6	58
70	CELLULAR BIOLOGY OF BONE RESORPTION. Biological Reviews, 1993, 68, 197-264.	4.7	57
71	TSH and Bone Loss. Annals of the New York Academy of Sciences, 2006, 1068, 309-318.	1.8	57
72	Bone, Inflammation, and Inflammatory Bowel Disease. Current Osteoporosis Reports, 2011, 9, 251-257.	1.5	57

#	Article	IF	Citations
73	Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17989-17994.	3.3	57
74	Modularity of osteoclast behaviour and â€œmode-specificâ€•inhibition of osteoclast function. Bioscience Reports, 1990, 10, 547-556.	1.1	54
75	Male Osteoporosis: Epidemiology and the Pathogenesis of Aging Bones. Current Osteoporosis Reports, 2011, 9, 229-236.	1.5	54
76	Blocking FSH action attenuates osteoclastogenesis. Biochemical and Biophysical Research Communications, 2012, 422, 54-58.	1.0	54
77	Functions of vasopressin and oxytocin in bone mass regulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 164-169.	3.3	54
78	Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5086-5095.	3.3	54
79	The Central Nervous System (CNS)-independent Anti-bone-resorptive Activity of Muscle Contraction and the Underlying Molecular and Cellular Signatures. Journal of Biological Chemistry, 2013, 288, 13511-13521.	1.6	53
80	Minireview: The Link Between Fat and Bone: Does Mass Beget Mass?. Endocrinology, 2012, 153, 2070-2075.	1.4	52
81	Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17995-18000.	3.3	52
82	â€œCalcium receptorsâ€•on eukaryotic cells with special reference to the osteoclast. Bioscience Reports, 1990, 10, 493-507.	1.1	51
83	Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. American Journal of Physiology - Renal Physiology, 2007, 292, F285-F291.	1.3	51
84	Activation of the Ca2+ ?receptor? on the osteoclast by Ni2+ elicits cytosolic Ca2+ signals: Evidence for receptor activation and inactivation, intracellular Ca2+ redistribution, and divalent cation modulation. Journal of Cellular Physiology, 1993, 155, 120-129.	2.0	50
85	Molecular and Functional Evidence for Calcineurin-A Î± and Î² Isoforms in the Osteoclast: Novel Insights into Cyclosporin A Action on Bone Resorption. Biochemical and Biophysical Research Communications, 1999, 254, 248-252.	1.0	50
86	NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP. Journal of Cell Science, 2005, 118, 5479-5487.	1.2	50
87	Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. Current Osteoporosis Reports, 2009, 7, 118-126.	1.5	49
88	Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11Î²-hydroxysteroid dehydrogenase type 2 deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E11248-E11256.	3.3	48
89	Selective antagonism of calcitonin-induced osteoclastic quiescence (Q effect) by human calcitonin gene-related peptide-(Val8Phe37). Biochemical and Biophysical Research Communications, 1991, 179, 134-139.	1.0	47
90	Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochemical and Biophysical Research Communications, 2011, 411, 512-515.	1.0	47

#	Article	IF	Citations
91	New Insights into the Regulation of Cathepsin K Gene Expression by Osteoprotegerin Ligand. Biochemical and Biophysical Research Communications, 2001, 285, 335-339.	1.0	46
92	Anabolic actions of Notch on mature bone. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2152-61.	3.3	46
93	Further evidence for direct pro-resorptive actions of FSH. Biochemical and Biophysical Research Communications, 2010, 394, 6-11.	1.0	45
94	Actions of pituitary hormones beyond traditional targets. Journal of Endocrinology, 2018, 237, R83-R98.	1.2	45
95	FSH Beyond Fertility. Frontiers in Endocrinology, 2019, 10, 136.	1.5	45
96	Calcium sensing and cell signaling processes in the local regulation of osteoclastic bone resorption. Biological Reviews, 2004, 79, 79-100.	4.7	44
97	Anabolic steroids reduce spinal cord injury-related bone loss in rats associated with increased Wnt signaling. Journal of Spinal Cord Medicine, 2013, 36, 616-622.	0.7	43
98	The osteoclast Ca2+ receptor is highly sensitive to activation by transition metal cations. Biochemical and Biophysical Research Communications, 1992, 187, 913-918.	1.0	41
99	Ca²⁺influx through the osteoclastic plasma membrane ryanodine receptor. American Journal of Physiology - Renal Physiology, 2002, 282, F921-F932.	1.3	41
100	Oxytocin deficiency impairs maternal skeletal remodeling. Biochemical and Biophysical Research Communications, 2009, 388, 161-166.	1.0	41
101	FSH, Bone Mass, Body Fat, and Biological Aging. Endocrinology, 2018, 159, 3503-3514.	1.4	40
102	Thyroid-stimulating hormone, thyroid hormones, and bone loss. Current Osteoporosis Reports, 2009, 7, 47-52.	1.5	38
103	Intracellular calcium in the control of osteoclast function. II. Paradoxical elevation of cytosolic free calcium by verapamil. Biochemical and Biophysical Research Communications, 1990, 167, 807-812.	1.0	36
104	Is the osteoclast calcium â€œreceptorâ€• a receptor-operated calcium channel?. Biochemical and Biophysical Research Communications, 1992, 183, 619-625.	1.0	36
105	Effects of electromagnetic stimulation on the functional responsiveness of isolated rat osteoclasts. , 1998, 176, 537-544.		35
106	Calcitonin: The Other Thyroid Hormone. Thyroid, 2002, 12, 791-798.	2.4	35
107	Genetic confirmation for a central role for TNFÂ in the direct action of thyroid stimulating hormone on the skeleton. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9891-9896.	3.3	35
108	First-in-class humanized FSH blocking antibody targets bone and fat. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28971-28979.	3.3	35

#	Article	IF	Citations
109	A quantitative description of components of in vitro morphometric change in the rat osteoclast model: relationships with cellular function. European Biophysics Journal, 1992, 21, 349-55.	1.2	34
110	Expanding the Role of Thyroid-Stimulating Hormone in Skeletal Physiology. Frontiers in Endocrinology, 2017, 8, 252.	1.5	34
111	Oxytocin regulates body composition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26808-26815.	3.3	34
112	Transient appearance of calcitonin gene-related peptide-like immunoreactive fibers in the developing cerebellum of the rat. Brain Research, 1987, 415, 385-388.	1.1	33
113	Proresorptive Actions of FSH and Bone Loss. Annals of the New York Academy of Sciences, 2007, 1116, 376-382.	1.8	33
114	Bone Loss in Thyroid Disease: Role of Low TSH and High Thyroid Hormone. Annals of the New York Academy of Sciences, 2007, 1116, 383-391.	1.8	33
115	Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochemical and Biophysical Research Communications, 2005, 328, 790-793.	1.0	32
116	Training the physician-scientist: views from program directors and aspiring young investigators. JCI Insight, 2018, 3, .	2.3	32
117	Evidence that a ryanodine receptor triggers signal transduction in the osteoclast. Biochemical and Biophysical Research Communications, 1992, 188, 1332-1336.	1.0	31
118	Linkage of extracellular and intracellular control of cytosolic Ca2+ in rat osteoclasts in the presence of thapsigargin. Journal of Bone and Mineral Research, 1993, 8, 961-967.	3.1	31
119	Emerging concepts in the epidemiology, pathophysiology, and clinical care of osteoporosis across the menopausal transition. Matrix Biology, 2018, 71-72, 70-81.	1.5	31
120	Coupling bone degradation to formation. Nature Medicine, 2009, 15, 729-731.	15.2	30
121	Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation. Annals of the New York Academy of Sciences, 2010, 1192, 303-306.	1.8	30
122	MicroRNA 874-3p Exerts Skeletal Anabolic Effects Epigenetically during Weaning by Suppressing Hdac1 Expression. Journal of Biological Chemistry, 2016, 291, 3959-3966.	1.6	30
123	Serum FSH Is Associated With BMD, Bone Marrow Adiposity, and Body Composition in the AGES-Reykjavik Study of Older Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1156-e1169.	1.8	30
124	Intracellular calcium in the control of osteoclast function I. Voltage-insensitivity and lack of effects of nifedipine, BAYK8644 and diltiazem. Biochemical and Biophysical Research Communications, 1990, 167, 183-188.	1.0	29
125	Calcitonin: Physiological Actions and Clinical Applications. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 931-40.	0.4	29
126	The effect of extracellularly applied divalent cations on cytosolic Ca2+in murine Leydig cells: evidence for a Ca2+-sensing receptor. Journal of Physiology, 1998, 513, 399-410.	1.3	28

#	Article	IF	Citations
127	Novel biochemical and functional insights into nuclear Ca²⁺transport through IP₃Rs and RyRs in osteoblasts. American Journal of Physiology - Renal Physiology, 2000, 278, F784-F791.	1.3	28
128	The Developmental Basis of Skeletal Cell Differentiation and the Molecular Basis of Major Skeletal Defects. Biological Reviews, 2008, 83, 401-415.	4.7	28
129	Novel Mechanisms of Calcium Handling by the Osteoclast: A Review-Hypothesis. Proceedings of the Association of American Physicians, 1999, 111, 319-327.	2.1	28
130	Cyclosporine And Cremaphor Modulate Von Willebrand Factor Release From Cultured Human Endothelial Cells. Transplantation, 1993, 56, 1218-1222.	0.5	27
131	HIV and Bone Loss. Current Osteoporosis Reports, 2010, 8, 219-226.	1.5	27
132	Oxytocin and bone. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 307, R970-R977.	0.9	27
133	FSIP1 regulates autophagy in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 13075-13080.	3.3	27
134	Activation and inactivation of the osteoclast Ca2+ receptor by the trivalent cation, La3+. Biochemical and Biophysical Research Communications, 1992, 187, 907-912.	1.0	26
135	Identification and Characterization of a Sodium/Calcium Exchanger, NCX-1, in Osteoclasts and Its Role in Bone Resorption. Biochemical and Biophysical Research Communications, 2001, 283, 770-775.	1.0	26
136	Low TSH Triggers Bone Loss: Fact or Fiction?. Thyroid, 2006, 16, 1075-1076.	2.4	26
137	Understanding Estrogen Action during Menopause. Endocrinology, 2009, 150, 3443-3445.	1.4	26
138	Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells. Biochemical and Biophysical Research Communications, 2010, 394, 715-720.	1.0	26
139	Skeletal receptors for steroidâ€family regulating glycoprotein hormones. Annals of the New York Academy of Sciences, 2011, 1240, 26-31.	1.8	26
140	Amylin in bone conservation current evidence and hypothetical Considerations. Trends in Endocrinology and Metabolism, 1993, 4, 255-259.	3.1	25
141	TNF-induced gene expression oscillates in time. Biochemical and Biophysical Research Communications, 2008, 371, 900-905.	1.0	25
142	Calcitonin and bone formation: a knockout full of surprises. Journal of Clinical Investigation, 2002, 110, 1769-1771.	3.9	25
143	Implementing a "publish, then review" model of publishing. ELife, 2020, 9, .	2.8	25
144	A Possible New Role for Vitamin D-Binding Protein in Osteoclast Control: Inhibition of Extracellular Ca2+Sensing at Low Physiological Concentrations. Biochemical and Biophysical Research Communications, 1998, 249, 668-671.	1.0	24

#	Article	IF	Citations
145	Structure and functional regulation of the CD38 promoter. Biochemical and Biophysical Research Communications, 2006, 341, 804-809.	1.0	24
146	Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness. Journal of Intensive Care Medicine, 2012, 27, 312-318.	1.3	24
147	Expression and Function of the Calcitonin Gene Products. Vitamins and Hormones, 1991, 46, 87-164.	0.7	23
148	Selective upregulation of the ADP-ribosyl cyclases CD38 and CD157 by TNF but not by RANK-L reveals differences in downstream signaling. American Journal of Physiology - Renal Physiology, 2006, 291, F557-F566.	1.3	23
149	The Role of FSH and TSH in Bone Loss and Its Clinical Relevance. Current Osteoporosis Reports, 2010, 8, 205-211.	1.5	23
150	Regulation of bone turnover by calciumâ€regulated calcium channels. Annals of the New York Academy of Sciences, 2010, 1192, 351-357.	1.8	23
151	The NOâ€“cGMPâ€“PKG pathway in skeletal remodeling. Annals of the New York Academy of Sciences, 2021, 1487, 21-30.	1.8	23
152	Functional grouping of osteoclast genes revealed through microarray analysis. Biochemical and Biophysical Research Communications, 2008, 366, 352-359.	1.0	22
153	Vitamin C Prevents Hypogonadal Bone Loss. PLoS ONE, 2012, 7, e47058.	1.1	22
154	FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7683-7688.	3.3	22
155	FSH-metabolic circuitry and menopause. Journal of Molecular Endocrinology, 2019, 63, R73-R80.	1.1	22
156	A dual effect of calcitonin gene-related peptide on plasma calcium levels in the chick. Biochemical and Biophysical Research Communications, 1990, 169, 846-850.	1.0	21
157	Neural surveillance of skeletal homeostasis. Cell Metabolism, 2005, 1, 219-221.	7.2	21
158	Response: Both FSH and Sex Steroids Influence Bone Mass. Cell, 2006, 127, 1080-1081.	13.5	21
159	Evaluating the Antifracture Efficacy of Bisphosphonates. Reviews on Recent Clinical Trials, 2009, 4, 122-130.	0.4	21
160	From the gut to the strut: where inflammation reigns, bone abstains. Journal of Clinical Investigation, 2016, 126, 2045-2048.	3.9	21
161	Effect of membrane potential on surface Ca2+ receptor activation in rat osteoclasts. Journal of Cellular Physiology, 1995, 162, 1-8.	2.0	20
162	Denosumab for the Treatment of Osteoporosis. Current Osteoporosis Reports, 2010, 8, 163-167.	1.5	20

#	Article	IF	Citations
163	A new approach for calcitonin determination based on target cell responsiveness. Journal of Endocrinological Investigation, 1990, 13, 119-126.	1.8	19
164	Tetracyclines modulate cytosolic Ca2+ responses in the osteoclast associated with â€œCa2+ receptorâ€• activation. Bioscience Reports, 1993, 13, 169-174.	1.1	19
165	Further evidence that FSH causes bone loss independently of low estrogen. Endocrine, 2012, 41, 171-175.	1.1	19
166	Transforming growth factor-Î²-induced mitogenesis of human bone cancer cells. Biochemical and Biophysical Research Communications, 1989, 161, 672-676.	1.0	18
167	Modulation of the Osteoclast Ca2+ Receptor by Extracellular Protons: Possible Linkage Between Ca2+ Sensing and Extracellular Acidification. Biochemical and Biophysical Research Communications, 1994, 199, 742-747.	1.0	18
168	Role of the pituitary-bone axis in skeletal pathophysiology. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 423-429.	1.2	18
169	The Ã¢â‚¬Å“Love HormoneÃ¢â‚¬Â•Oxytocin Regulates the Loss and Gain of the FatÃ¢â‚¬â€œBone Relationship. Frontiers in Endocrinology, 2015, 6, 79.	1.5	18
170	The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry. ELife, 2021, 10, .	2.8	18
171	Stimulation of a Gs-like G Protein in the Osteoclast Inhibits Bone Resorption but Enhances Tartrate-Resistant Acid Phosphatase Secretion. Biochemical and Biophysical Research Communications, 1993, 190, 496-501.	1.0	17
172	Direct Microsensor Measurement of Nitric Oxide Production by the Osteoclast. Biochemical and Biophysical Research Communications, 1999, 259, 73-77.	1.0	17
173	Extracellular NAD+ metabolism modulates osteoclastogenesis. Biochemical and Biophysical Research Communications, 2006, 349, 533-539.	1.0	17
174	Identification of CITED2 as a negative regulator of fracture healing. Biochemical and Biophysical Research Communications, 2009, 387, 641-645.	1.0	17
175	Macrophage Colony-Stimulating Factor Suppresses Osteoblast Formation. Biochemical and Biophysical Research Communications, 2001, 285, 328-334.	1.0	16
176	The crossover of bisphosphonates to cancer therapy. Annals of the New York Academy of Sciences, 2010, 1211, 107-112.	1.8	16
177	Questioning the association between bisphosphonates and atypical femoral fractures. Annals of the New York Academy of Sciences, 2015, 1335, 1-9.	1.8	16
178	Intravenous Pamidronate is Associated with Reduced Mortality in Patients with Chronic Critical Illness. Endocrine Practice, 2016, 22, 799-808.	1.1	16
179	Cytochrome c oxidase dysfunction enhances phagocytic function and osteoclast formation in macrophages. FASEB Journal, 2019, 33, 9167-9181.	0.2	16
180	Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14386-14394.	3.3	16

#	Article	IF	Citations
181	The effect of tetracyclines on quantitative measures of osteoclast morphology. Bioscience Reports, 1993, 13, 175-182.	1.1	15
182	Extracellular Cation Sensing by the Enterocyte: Prediction of a Novel Divalent Cation "Receptor". Biochemical and Biophysical Research Communications, 1995, 210, 948-953.	1.0	15
183	Molecular cloning, expression, and function of osteoclastic calcineurin AÎ±. American Journal of Physiology - Renal Physiology, 2003, 284, F575-F583.	1.3	15
184	Double protection for weakened bones. Nature, 2012, 485, 47-48.	13.7	15
185	Pituitary-bone connection in skeletal regulation. Hormone Molecular Biology and Clinical Investigation, 2016, 28, 85-94.	0.3	15
186	Best Practices for Physician-Scientist Training Programs: Recommendations from the Alliance for Academic Internal Medicine. American Journal of Medicine, 2018, 131, 578-584.	0.6	15
187	A highly specific and sensitive enzyme-immunometric assay for calcitonin gene-related peptide based on enzyme amplification. Journal of Immunological Methods, 1988, 111, 11-16.	0.6	14
188	Production and characterisation of immunoreactive calcitonin gene-related peptide (CGRP) from a CGRP receptor-positive cloned osteosarcoma cell line (UMR 106.01). Biochemical and Biophysical Research Communications, 1989, 158, 214-219.	1.0	14
189	Voltage Sensitivity of the Osteoclast Calcium Receptor. Biochemical and Biophysical Research Communications, 1993, 192, 1100-1105.	1.0	14
190	Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia. Endocrine Development, 2016, 30, 37-41.	1.3	14
191	A hypothesis for the local control of osteoclast function by Ca2+, nitric oxide and free radicals. Bioscience Reports, 1992, 12, 369-380.	1.1	13
192	New insights: Elevated follicle-stimulating hormone and bone loss during the menopausal transition. Current Rheumatology Reports, 2009, 11, 191-195.	2.1	13
193	Complexity in signal transduction. Annals of the New York Academy of Sciences, 2010, 1192, 238-244.	1.8	13
194	The high-density lipoprotein receptor Scarb1 is required for normal bone differentiation in vivo and in vitro. Laboratory Investigation, 2019, 99, 1850-1860.	1.7	13
195	Opening windows for bone remodeling through a SLIT. Journal of Clinical Investigation, 2018, 128, 1255-1257.	3.9	13
196	Commentary-FSH and bone 2010: evolving evidence. European Journal of Endocrinology, 2010, 163, 173-176.	1.9	12
197	Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice. Biochemical and Biophysical Research Communications, 2012, 422, 573-577.	1.0	12
198	Contemporaneous reproduction of preclinical science: a case study of FSH and fat. Annals of the New York Academy of Sciences, 2017, 1404, 17-19.	1.8	12

#	Article	IF	Citations
199	Free radical pathways in the inflammatory response. New Comprehensive Biochemistry, 1994, , 361-383.	0.1	11
200	Special Stem Cells for Bone. Cell Stem Cell, 2012, 10, 233-234.	5.2	11
201	A rare <i>CYP21A2</i> mutation in a congenital adrenal hyperplasia kindred displaying genotypeâ€"phenotype nonconcordance. Annals of the New York Academy of Sciences, 2016, 1364, 5-10.	1.8	11
202	Understanding osteoclast formation and function: implications for future therapies for osteoporosis. Current Opinion in Orthopaedics, 2003, 14, 341-350.	0.3	10
203	CD38 is required for priming by TNF-Î±: a mechanism for extracellular coordination of cell fate. American Journal of Physiology - Renal Physiology, 2007, 292, F1283-F1290.	1.3	10
204	Cellular and Molecular Consequences of Calcineurin AÂ Gene Deletion. Annals of the New York Academy of Sciences, 2007, 1116, 216-226.	1.8	10
205	Receptor becomes a ligand to control bone remodelling. Nature, 2018, 561, 180-181.	13.7	10
206	Thyrotropin, Hyperthyroidism, and Bone Mass. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4809-e4821.	1.8	10
207	Osteoporosis: trends and intervention. Mount Sinai Journal of Medicine, 2002, 69, 220-31.	1.9	10
208	Progression of Efficacy with Ibandronate: A Paradigm for the Development of New Bisphosphonates. Annals of the New York Academy of Sciences, 2007, 1117, 273-282.	1.8	9
209	TNF-induced MAP kinase activation oscillates in time. Biochemical and Biophysical Research Communications, 2008, 371, 906-911.	1.0	9
210	Enhanced osteoclastogenesis by mitochondrial retrograde signaling through transcriptional activation of the cathepsin K gene. Annals of the New York Academy of Sciences, 2016, 1364, 52-61.	1.8	9
211	FSH Level and Changes in Bone Mass and Body Composition in Older Women and Men. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2876-2889.	1.8	9
212	The role of PDGF-BB in the bone-vascular relationship during aging. Journal of Clinical Investigation, 2021, 131, .	3.9	9
213	Single pulses of cytoplasmic calcium associated with phagocytosis of individual zymosan particles by macrophages. Biochemical and Biophysical Research Communications, 1991, 177, 460-465.	1.0	8
214	Modeling of Serum C-Telopeptide Levels with Daily and Monthly Oral Ibandronate in Humans. Annals of the New York Academy of Sciences, 2006, 1068, 560-563.	1.8	8
215	TNF-induced oscillations in combinatorial transcription factor binding. Biochemical and Biophysical Research Communications, 2008, 371, 912-916.	1.0	8
216	Clinical, Cellular and Molecular Phenotypes of Aging Bone. Interdisciplinary Topics in Gerontology, 2010, 37, 175-192.	3.6	8

#	Article	IF	Citations
217	Closing the loop on the bone-resorbing osteoclast. Nature Medicine, 2016, 22, 460-461.	15.2	8
218	A novel mutation in <i>HSD11B2</i> causes apparent mineralocorticoid excess in an Omani kindred. Annals of the New York Academy of Sciences, 2016, 1376, 65-71.	1.8	8
219	Upregulation of Functional Ryanodine Receptors duringin VitroAging of Human Diploid Fibroblasts. Biochemical and Biophysical Research Communications, 1998, 245, 50-52.	1.0	7
220	Molecular Cloning, Expression, and Functional Characterization of a Novel Member of the CD38 Family of ADP-ribosyl Cyclases. Biochemical and Biophysical Research Communications, 2000, 273, 884-889.	1.0	7
221	Molecular and Clinical Pharmacology of Calcitonin. , 2002, , 1423-1440.		7
222	Restoration of Bone Mass in Hpg Mouse by Preoptic Area Grafting. Annals of the New York Academy of Sciences, 2006, 1068, 341-347.	1.8	7
223	Regulation of FSH receptor promoter activation in the osteoclast. Biochemical and Biophysical Research Communications, 2007, 361, 910-915.	1.0	7
224	Similarities and Contrasts in Ryanodine Receptor Localization and Function in Osteoclasts and Striated Muscle Cells. Annals of the New York Academy of Sciences, 2007, 1116, 255-270.	1.8	7
225	MAF1, a repressor of RNA polymerase III-dependent transcription, regulates bone mass. ELife, 0, 11, .	2.8	7
226	Anti-Cancer Actions of Denosumab. Current Osteoporosis Reports, 2011, 9, 173-176.	1.5	6
227	Skeletal morphofunctional considerations and the pituitary-thyroid axis. Frontiers in Bioscience - Scholar, 2009, S1, 92-107.	0.8	6
228	Tumour stem cells in bone. Nature, 2013, 499, 414-416.	13.7	5
229	Erythroferrone Regulates Bone Remodeling in Î²-Thalassemia. Blood, 2019, 134, 2-2.	0.6	5
230	Reverse cholesterol transport and hepatic osteodystrophy. Cell Metabolism, 2022, 34, 347-349.	7.2	5
231	Paradigm Shift in the Pathophysiology of Postmenopausal and Thyrotoxic Osteoporosis. Mount Sinai Journal of Medicine, 2009, 76, 474-483.	1.9	4
232	New Horizons in Skeletal Physiology and Pathophysiology. Endocrine Practice, 2010, 16, 874-881.	1.1	4
233	Adrenergic stimulation decreases osteoblast oxytocin synthesis. Annals of the New York Academy of Sciences, 2011, 1237, 53-57.	1.8	4
234	Cinacalcet hydrochloride (Amgen). IDrugs: the Investigational Drugs Journal, 2003, 6, 587-92.	0.7	4

#	Article	IF	Citations
235	Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy. Gender Medicine, 2008, 5, 374-384.	1.4	3
236	Bone resorption goes green. Cell, 2021, 184, 1137-1139.	13.5	3
237	Overview: Inhibitors of Bone Resorption and Implications for Therapy. Current Opinion in Therapeutic Patents, 1992, 2, 1517-1538.	0.2	2
238	Direct Microsensor Measurement of Nitric Oxide Production by the Osteoclast. Biochemical and Biophysical Research Communications, 1999, 265, 770.	1.0	2
239	Cell signaling. Annals of the New York Academy of Sciences, 2010, 1211, 3-8.	1.8	2
240	Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach. Current Drug Therapy, 2010, 5, 48-57.	0.2	2
241	Endothelial cells revealed as chondroclasts. Nature Cell Biology, 2019, 21, 417-419.	4.6	2
242	Getting Warmer: Following Oneâ€™s Gut to Build Bone. Cell Metabolism, 2020, 32, 504-506.	7.2	2
243	Rigorous review and editorial oversight of clinical preprints. ELife, 2021, 10, .	2.8	2
244	Osteoclast Biology. , 2010, , 113-129.		2
245	Observations on Ca2+ entry into cultured human term trophoblasts via a putative Ca2+-operated Ca2+ channel. Placenta, 1992, 13, A4.	0.7	1
246	Elevated cytosolic calcium levels in human lymphocytes during surface virus infections. Molecular and Cellular Biochemistry, 1994, 131, 61-66.	1.4	1
247	Ca2+ channels in human term trophoblast cells in vitro. A study using the Ca2+-sensitive dye fura 2. Placenta, 1994, 15, 573-580.	0.7	1
248	Genetics and Cell Biology of Calcitonin Action. Principles of Medical Biology, 1997, , 601-616.	0.1	1
249	Molecules, mechanisms, and momentum in bone and cartilage research. Biochemical and Biophysical Research Communications, 2005, 328, 647-650.	1.0	1
250	TSH and Thyroid Hormones Both Regulate Bone Mass. Clinical Reviews in Bone and Mineral Metabolism, 2008, 6, 95-100.	1.3	1
251	Introduction to <i>Molecular and Integrative Physiology of the Musculoskeletal System</i>. Annals of the New York Academy of Sciences, 2010, 1211, 1-2.	1.8	1
252	Reply to Graham et al.: In silico atomistic coordinates and molecular dynamics simulation trajectories of the glucocerebrosidaseâ€“saposin C complex. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11101-11102.	3.3	1

#	Article	IF	Citations
253	The Human TSHÎ² Subunit Proteins and Their Binding Sites on the TSH Receptor Using Molecular Dynamics Simulation. Endocrinology, 2020, 161, .	1.4	1
254	Pituitary Hormone-Driven Mechanism for Skeletal Loss. Molecular and Integrative Toxicology, 2017, , 317-334.	0.5	1
255	Molecular Effects of Calcineurin Inhibitors. , 2005, , 79-89.		1
256	Cathepsin K and Bone Resorption. , 2020, , 273-278.		1
257	Extracellular Calcium Ion Sensing in Osteoclasts. Advances in Organ Biology, 1998, , 371-383.	0.1	0
258	Molecular Pharmacology of Antiresorptive Therapy for Osteoporosis. Advances in Organ Biology, 1998, , 809-834.	0.1	0
259	Editorial: Skeletal Biology and Skeletal Medicine. Annals of the New York Academy of Sciences, 2006, 1068, xvii-xvii.	1.8	0
260	Drug Repurposing by Connectivity Mapping and Structural Modeling. , 2019, , 609-623.		0
261	The Life and Works of Solomon Epstein, MD, FRCP (1940â€"2020). Journal of Bone and Mineral Research, 2020, 35, 829-830.	3.1	0
262	Participation in Health Services/Population Health Research in US Departments of Medicine. American Journal of Medicine, 2020, 133, 1354-1359.	0.6	0
263	Beyond bone biology: Lessons from team science. Journal of Orthopaedic Research, 2020, 38, 2331-2338.	1.2	0
264	Biology of Calcitonin as An Osteoprotective Agent. , 2020, , 599-607.		0
265	Transplantation Bone Disease Induced by Non-Steroid Immunosuppressants. , 2005, , 61-77.		0
266	Osteoclast Biology. , 2008, , 151-167.		0
267	The Pituitary-Bone Axis. Advances in Experimental Medicine and Biology, 2011, 707, 119-123.	0.8	0
268	Pituitary Hormones and the Pathophysiology of Osteoporosis. , 2012, , 87-100.		0
269	Metabolic Bone Disease Following Organ Transplantation. , 2015, , 185-206.		0
270	SAT-558 Tsh Modulation Of Bone Biology - Further Evidence From A Recombinant Tsh-Î² Variant.. Journal of the Endocrine Society, 2019, 3, .	0.1	0

#	Article	IF	Citations
271	Posttransplant Bone Loss. , 2020, , 23-32.		0
272	In Memoriam 2020. Journal of Bone and Mineral Research, 2020, 35, 2470-2470.	3.1	0
273	Convergence Research Unmasks Drug Targets Beyond Bone. , 2020, , 723-729.		0
274	Bone Loss and Body Composition Across The Menopausal Transition. , 2020, , 1-9.		0
275	Cellular Ionic Homeostatic Processes in Osteoclastic Bone Resorption. , 2020, , 279-289.		0
276	Regulation of Bone Mass and Body Composition by Anterior Pituitary Hormones. , 2020, , 503-518.		0
277	Metabolic Bone Disease and Osteoporosis. , 2022, , 119-146.		0
278	Solid Organ Transplantation, Chronic Renal Impairment, and Skeletal Complications. , 2008, , 223-228.		0